407 related articles for article (PubMed ID: 7751885)
41. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
42. [Radical cystectomy for superficial tumors in the BCG era].
Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
[TBL] [Abstract][Full Text] [Related]
43. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Krege S; Giani G; Meyer R; Otto T; Rübben H
J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
[TBL] [Abstract][Full Text] [Related]
44. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
45. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
[TBL] [Abstract][Full Text] [Related]
46. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
[TBL] [Abstract][Full Text] [Related]
47. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
48. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
Martínez-Piñeiro JA; Martínez-Piñeiro L; Solsona E; Rodríguez RH; Gómez JM; Martín MG; Molina JR; Collado AG; Flores N; Isorna S; Pertusa C; Rabadán M; Astobieta A; Camacho JE; Arribas S; Madero R;
J Urol; 2005 Oct; 174(4 Pt 1):1242-7. PubMed ID: 16145378
[TBL] [Abstract][Full Text] [Related]
49. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
[TBL] [Abstract][Full Text] [Related]
50. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
51. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
52. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
53. Results of transurethral resection plus adjuvant intravesical chemotherapy for superficial bladder cancer.
Nomi M; Gohji K; Okamoto M; Takenaka A; Ono Y; Fujii A
Int J Urol; 1998 Nov; 5(6):534-9. PubMed ID: 9855120
[TBL] [Abstract][Full Text] [Related]
54. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
55. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
56. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
57. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
58. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
[TBL] [Abstract][Full Text] [Related]
59. Total cystectomy after intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer: experience in Japan.
Takashi M; Kondo A; Nakano Y; Takagi Y; Sakata T; Miyake K
Int Urol Nephrol; 1994; 26(1):33-42. PubMed ID: 8026921
[TBL] [Abstract][Full Text] [Related]
60. The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Krajewski W; Zdrojowy R; Dembowski J; Poletajew S; Wróbel M; Łuczak M; Tukiendorf A; Kolodziej A
Urol Int; 2019; 102(1):60-68. PubMed ID: 30269132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
